Commercial clinical trials in the UK took an average of 100 days to set up in the three months to March 2026, according to newly released government figures. That compares with 153 days in the same three-month period a year earlier, a reduction of 53 days, or about 35 per cent. The figures mark progress against a national target, but they measure preparation before a trial begins, not how long research takes or whether a treatment works.
All 24 commercial trials set up between January and March 2026 were reported to have met the 150-day limit. The target set for March 2026 was for at least 95 per cent of commercial trials to be set up within 150 days. A separate earlier measure recorded 73 per cent meeting the target in the first half of 2025/26, compared with 45 per cent in 2024/25. The latest result therefore exceeds the stated threshold, although the quarter’s result represents a relatively small group of studies.
The figures describe a specific part of the research process. Set-up covers the period needed to prepare a study to start at a participating site. It is not the same as the time needed to recruit enough volunteers, complete follow-up, analyse results or make a medicine available through the NHS. Faster preparation may allow researchers to begin sooner and can help sponsors plan, but it does not by itself guarantee that a patient will be eligible for a study or benefit from its treatment.
The update also reports that every study receiving combined Medicines and Healthcare products Regulatory Agency and research ethics committee approval in September 2026 did so within 60 days. That is a separate regulatory-review measure from the 100-day average for commercial trial set-up. Keeping the two measures distinct matters: a review decision is one stage in the process, while wider set-up includes work needed to make a study ready to run.
Examples illustrate how quickly individual studies can move through parts of the system, but they should not be mistaken for typical results. The government highlighted the BEATRIX study, which offers pregnant women a vaccine against group B streptococcus, as reaching delivery in less than 150 days. It also said the CHILL study screened its first participant 113 days after entering set-up. Moderna’s Nova 301 study recruited 2,500 volunteers in nine weeks. These examples concern different milestones and do not establish that all studies recruit at a similar pace.
The government says its wider programme includes a National Institute for Health and Care Research Industry Hub and a network of Commercial Research Delivery Centres, alongside changes to regulation, contracting and research capacity. Those measures are intended to make the UK a more predictable place for sponsors to conduct studies. The figures released so far provide evidence of faster set-up, but they do not show on their own whether recruitment has increased across the whole research system or whether the gains are consistent between locations and types of trial.
For patients, the practical significance is potential rather than automatic access. A trial must still recruit participants, complete its work and produce evidence that regulators and clinicians can assess. The government’s update is a notable improvement against its timetable, while the next test is whether quicker starts translate into more people being able to take part and whether the system can sustain the result beyond one quarter.
